Acute coronary syndrome
229 results
1 - 100
Presence of risk factors doesn't predict acute coronary syndrome- Clinical decision helpful in diagnosis of acute coronary syndrome in primary care
- Patients with non-ST-elevation acute coronary syndromes do not need immediate intervention
- Escitalopram reduces risk of adverse cardiac events in adults with depression and acute coronary syndrome
- For treatment of acute coronary syndrome, prasugrel is better than ticagrelor at preventing recurrent MIs at 1 year
- PSK9 inhibitor alirocumab reduces nonfatal MI in patients after acute coronary syndrome, but at high cost (ODYSSEY OUTCOMES)
- Early CT angiography for suspected acute coronary syndrome reduces further ischemic testing; no effect on long-term clinical outcomes
- After 1 month of DAPT after PCI for acute coronary syndromes, ticagrelor monotherapy results in similar outcomes with less bleeding than ticagrelor plus aspirin
- Dabigatran associated with increased risk of coronary events
- Ranolazine (Ranexa) not effective for ACS
- Less bleeding with fondaparinux vs enoxaparin for ACS with PCI
- Signs and symptoms not helpful in diagnosis of AMI/ACS
- FDA: Clopidogrel/aspirin does not decrease overall mortality
- Coronary CT angiogram allows for safe discharge of low-risk patients with chest pain
- Faster discharge but more downstream testing with use of CCTA in ED
- Additional testing of limited benefit in patients with new-onset chest pain
- Pain severity does not predict outcomes with AMI
- Intensive lipid lowering reduces mortality following ACS
- Bivalirudin = abciximab + heparin for non-STEMI
- For atrial fibrillation with ACS or PCI, apixaban plus clopidogrel (without aspirin) is preferred (AUGUSTUS)
- Intensive lipid lowering adds additional benefit
- Improved outcomes with early invasive strategy for ACS? Maybe, maybe not.
- ED chest pain protocol is safe and efficient
- Ruling out acute myocardial infarction based on patient characteristics
- Low-dose rivaroxaban improves outcomes in patients with ACS (ATLAS)
- Two-hour protocol identifies patients at low risk of ACS
- Genotype-guided selection of oral P2Y12 inhibitor therapy no better than standard therapy after PCI for ACS or stable CAD
- Mortality rate in patients with recent ACS and endoscopy is similar to that in patients with ACS and no endoscopy
- Apixaban increases bleeding with no benefit in high-risk patients with ACS
- No reduction in postdischarge medication errors after pharmacist-led intervention
- Invasive strategy best only for men and high-risk women with unstable angina/non-ST elevation MI
- Concomitant use of clopidogrel and a PPI may increase risk of adverse CHD outcomes
- Early invasive therapy better for non-ST ACS
- CCTA reduces need for hospitalization in low to moderate risk patients in ED
- Better medication adherence with intervention; clinical outcomes unchanged
- Clopidogrel + ASA no better than ASA alone for high-risk patients
- Routine stress testing after negative biomarker testing seldom helpful